Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O link é salvo na área de transferência
StatusRescindido
Patrocinadores
Boneca Corporation

Palavras-chave

Resumo

Boron Neutron Capture Therapy (BNCT) is an experimental radiation therapy technique that is based on the principle of irradiating boron atoms with neutrons. When neutrons have relatively low energy, boron atoms that have been targeted to cancerous tissue using a suitable boron carrier (an amino acid derivative called BPA, boronophenylalanine) will capture the neutrons. As a result from the neutron capture the boron atoms will split into two, producing helium and lithium ions. The helium and lithium ions, in turn, have only a short pathlength in tissue (about 5 micrometers) and will deposit their cell damaging effect mainly within the tumor provided that the boron carrier (BPA) has accumulated in the tumor. In practice, the study participants will receive BPA as an approximately 2-hour intravenous infusion, following which the tumor is irradiated with low energy (epithermal) neutrons obtained from a nuclear reactor at the BNCT facility. BNCT requires careful radiation dose planning, but neutron irradiation will last approximately only for one hour. In this study BNCT is given only once. The study hypothesis is that glioblastoma tissue may accumulate the boron carrier compound, and glioblastoma might respond to BNCT.

Descrição

This is a single BNCT-facility, non-randomized, non-comparative, prospective, open-label, phase I/II trial to determine the value of BNCT in the treatment of subjects who have undergone surgery for glioblastoma, but glioblastoma has not been treated with radiation therapy or chemotherapy. The neutron irradiation site is the FiR 1 reactor site, located at Otaniemi, Espoo, Finland, about 6 kilometers from the Helsinki University Central Hospital, Helsinki, where patient evaluation and post-irradiation care will take place.

BPA is infused as a fructose complex (BPA-F) into a peripheral vein over 2 hours prior to neutron irradiation. Blood samples will be taken before starting the BPA infusion, and thereafter at 20 to 40 minute intervals during the infusion, following infusion, and after delivering neutron irradiation to monitor the blood boron concentration. The blood samples will be analyzed for boron to estimate the average blood boron level during neutron irradiation. The first 12 patients are treated using a BPA dose of 290 mg/kg, following which the dose of BPA is increased stepwise to 500 mg/kg, provided that unacceptable toxicity will not occur.

All patients will be evaluated for response using CT or magnetic resonance imaging (MRI).

datas

Última verificação: 07/31/2008
Enviado pela primeira vez: 06/21/2005
Inscrição estimada enviada: 06/21/2005
Postado pela primeira vez: 06/22/2005
Última atualização enviada: 08/13/2008
Última atualização postada: 08/17/2008
Data real de início do estudo: 04/30/1999
Data Estimada de Conclusão Primária: 07/31/2008
Data Estimada de Conclusão do Estudo: 07/31/2008

Condição ou doença

Glioblastoma

Intervenção / tratamento

Radiation: A

Fase

Fase 1/Fase 2

Grupos de Armas

BraçoIntervenção / tratamento
Experimental: A
Active treatment arm.
Radiation: A
Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.

Critério de eleição

Idades qualificadas para estudar 18 Years Para 18 Years
Sexos elegíveis para estudoAll
Aceita Voluntários Saudáveissim
Critério

Inclusion Criteria:

- Histologically confirmed glioblastoma multiforme

- Supratentorial location

- At least 30% of the tumor volume has been removed at craniotomy as judged from a pre/perioperative MRI

- Ability to understand the concept of investigational therapy

- Tolerates dexamethasone treatment

- Adequate anti-epileptic medication

- BNCT can be delivered within 6 weeks from the date of brain surgery

- A written informed consent

Exclusion Criteria:

- Age less than 18 or greater than 75

- The tumor infiltrates into the optic chiasm or into the deep parts of the brain prohibiting delivery of an adequate radiation dose with BNCT

- Prior radiation therapy to the brain

- Prior chemotherapy, immunotherapy, or gene therapy

- Karnofsky performance score <70

- Severe cardiac, liver, or kidney failure

- Severe infection

- A cardiac pace-maker, or a metal implant in the head and neck region that will prohibit MRI examination

- Pregnancy or lactation

- Phenylketonuria

Resultado

Medidas de Resultado Primário

1. safety [3 years]

Medidas de Resultado Secundário

1. tumor response [one year]

2. effect on brain tissue [3 years]

Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge